2 型糖尿病市場規模、佔有率和成長分析：按藥物類別、給藥途徑、分銷管道、最終用戶和地區分類 - 產業預測，2024-2031 年

2022年全球2型糖尿病市場規模估值為340.7億美元，從2023年的368.7億美元增至2031年的665.2億美元，在預測期內（2024-2031年）預計複合年成長率為7.72% 。

據 NCBI 稱，全球糖尿病治療市場預計將從 2014 年的 8,900 萬例增至 3.3 億例，強勁成長主要是由 2 型糖尿病 (T2D) 激增推動。這種激增推動了醫學的進步，以創新療法的推出為代表，例如Glucagon-Like Peptide-1受體促效劑Tanzeum和Trulicity，以及Na-葡萄糖共同輸送體2抑制劑Jardiance。儘管取得了這些進步，但由於患者對現有治療方法的認知較低，市場成長仍面臨挑戰。相反，在迫切需要有效的糖尿病管理解決方案的發展中地區存在著巨大的機會。糖尿病盛行率的不斷上升進一步刺激了對更全面治療方案的需求，從而導致技術進步，從而實現更具適應性的醫療解決方案。雲端基礎的企業系統的興起以及連接設備和應用程式的普及是推動市場擴張的關鍵趨勢。然而，設備高成本、低收入國家資金籌措不足以及對傳統糖尿病管理技術的持續依賴等阻礙因素可能會阻礙該行業在預測期內的成長。總體而言，隨著醫學的不斷發展，技術和創新藥物療法的整合對於滿足全球糖尿病治療日益成長的需求至關重要。

目錄

介紹

• 研究目的
• 定義
• 市場範圍

調查方法

• 資訊採購
• 二手資料來源和主要資料來源
• 市場規模預測
• 市場假設與限制

執行摘要

• 市場概況展望
• 供需趨勢分析
• 按細分市場的機會分析

市場動態及展望

• 市場動態
  • 促進因素
  • 機會
  • 抑制因素
  • 任務
• 波特的分析

主要市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 技術分析
• 監管環境
• 專利分析
• PESTEL分析
• 管道分析
• 價格分析

2 型糖尿病市場：依藥物類別

• 市場概況
• Dipeptidyl Peptidase-4抑制劑
• 類升糖素胜肽1受體促效劑
• 雙胍
• 鈉-葡萄糖共同輸送體2 (SGLT2) 抑制劑
• 其他

2 型糖尿病市場：依給藥途徑

• 市場概況
• 口服
• 胃腸外的

2 型糖尿病市場：按分銷管道

• 市場概況
• 醫院藥房
• 零售藥房
• 網路藥房

2 型糖尿病市場：依最終用戶分類

• 市場概況
• 居家醫療
• 醫院/診所
• 學術/研究機構
• 其他

2 型糖尿病市場規模：依地區分類

• 市場概況
• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲 (MEA)
  • 海灣合作理事會國家
  • 南非
  • 其他中東/非洲地區

競爭格局

• 前5名企業對比
• 主要企業市場定位（2023年）
• 主要市場參與者所採取的策略
• 近期市集活動
• 主要企業市場佔有率（2023年）

主要企業簡介

• Novo Nordisk
• Sanofi
• Eli Lilly and Company
• Merck & Co., Inc.
• Boehringer Ingelheim
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Pfizer Inc.
• Daiichi Sankyo Company, Limited
• Roche Holding AG
• Sun Pharmaceutical Industries Ltd.
• Lupin Limited
• Dr. Reddy's Laboratories Ltd.
• Aurobindo Pharma Limited
• Medtronic
• B. Braun Melsungen AG
• Abbott Laboratories
• F. Hoffmann-La Roche
• Insulet Corporation

Global Type 2 Diabetes Market size was valued at USD 34.07 billion in 2022 and is poised to grow from USD 36.87 billion in 2023 to USD 66.52 billion by 2031, growing at a CAGR of 7.72% during the forecast period (2024-2031).

The global diabetes care market is experiencing robust growth, primarily driven by the alarming rise in type 2 diabetes (T2D) cases, which soared from 89 million in 2014 to an anticipated 330 million by 2022, according to NCBI. This surge has motivated pharmaceutical advances, exemplified by the introduction of innovative therapies such as glucagon-like peptide-1 receptor agonists Tanzeum and Trulicity, as well as the sodium glucose cotransporter 2 inhibitor Jardiance. Despite these advancements, market growth faces challenges due to low patient awareness surrounding available treatments. Conversely, substantial opportunities are projected in developing regions where there is a pressing need for effective diabetes management solutions. The increasing prevalence of diabetes has further intensified the demand for enhanced care options, leading to technological progress that allows for more adaptable healthcare solutions. The rise of cloud-based enterprise systems and the popularity of connected devices and apps are pivotal trends driving market expansion. However, impediments such as the high cost of devices, inadequate funding in lower-income nations, and the continued reliance on traditional diabetes management methods may hinder growth in this sector throughout the forecast period. Overall, as healthcare continues to evolve, the integration of technology and innovative drug therapies will be essential in meeting the escalating demand for diabetes care globally.

Top-down and bottom-up approaches were used to estimate and validate the size of the global type 2 diabetes market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

global type 2 diabetes Market Segmental Analysis

Global Type 2 Diabetes Market is segmented by Drug Class, Route of Administration, Distribution Channel, End User, and Region. Based on Drug Class, the market is segmented into Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide 1 Receptor Agonists, Biguanides, Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors, Others. Based on Route of Administration, the market is segmented into Oral, Parenteral. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies. Based on End User, the market is segmented into Homecare Settings, Hospitals & Clinics, Academic & Research Institutes, Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the global type 2 diabetes Market

The rapid advancement of artificial intelligence (AI) is emerging as a significant market driver for the global type 2 diabetes market, revolutionizing the diagnosis and management of this chronic condition. AI's ability to analyze vast amounts of health data through machine learning algorithms enables the development of predictive models that assess individual risk of developing diabetes and its complications. This shift towards precision medicine fosters more personalized and effective treatment strategies, replacing traditional management techniques with data-driven approaches. As healthcare systems increasingly adopt these AI-enhanced solutions, the demand for innovative products and services in the type 2 diabetes space is expected to surge, fueling market growth.

Restraints in the global type 2 diabetes Market

The global type 2 diabetes market faces significant restraint from the lack of reimbursement systems in underdeveloped nations, which often leads to treatment non-compliance among patients. In countries like China and India, individuals are burdened with out-of-pocket expenses for essential diabetes management tools such as continuous glucose monitoring (CGM) systems, insulin, and blood glucose monitors. This financial strain limits access to integrated digital diabetes management solutions, subsequently hindering their widespread adoption in these regions. As the disparity in healthcare funding persists, the growth potential of the type 2 diabetes market in emerging economies may be stifled, affecting overall market expansion.

Market Trends of the global type 2 diabetes Market

The global type 2 diabetes market is increasingly trending towards personalized medicine, driven by advancements in digital health technologies and genetic testing. This customized approach tailors treatment plans to the individual characteristics of patients-including their genetic makeup, lifestyle factors, and comorbidities-aiming to optimize therapeutic outcomes. As healthcare providers recognize the importance of personalized solutions, there is a growing emphasis on enhancing patient adherence and minimizing side effects. This shift not only reflects the evolving expectations of patients seeking more effective and convenient treatments but also indicates a significant opportunity for innovative companies to leverage technology in delivering bespoke care in the diabetes sector.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Technology Analysis
• Regulatory Landscape
• Patent Analysis
• PESTEL Analysis
• Pipeline Analysis
• Pricing Analysis

Type 2 Diabetes Market, by Drug Class

• Market Overview
• Dipeptidyl Peptidase-4 Inhibitors
• Glucagon-like peptide 1 receptor agonists
• Biguanides
• Sodium-glucose cotransporter 2 (SGLT2) inhibitors
• Others

Type 2 Diabetes Market, by Route of Administration

• Market Overview
• Oral
• Parenteral

Type 2 Diabetes Market, by Distribution Channel

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Type 2 Diabetes Market, by End User

• Market Overview
• Homecare Settings
• Hospitals & Clinics
• Academic & Research Institutes
• Others

Type 2 Diabetes Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Novo Nordisk
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Company, Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lupin Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medtronic
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• B. Braun Melsungen AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Insulet Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments